Knight Therapeutics Inc. (TSE:GUD – Get Free Report) insider Sime Armoyan purchased 351,000 shares of Knight Therapeutics stock in a transaction dated Monday, March 25th. The stock was bought at an average price of C$5.25 per share, with a total value of C$1,842,750.00.
Sime Armoyan also recently made the following trade(s):
- On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$162,150.00.
- On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$523,250.00.
Knight Therapeutics Stock Performance
Shares of GUD stock opened at C$5.44 on Thursday. The company’s fifty day simple moving average is C$5.46 and its 200-day simple moving average is C$5.12. The company has a quick ratio of 1.79, a current ratio of 3.20 and a debt-to-equity ratio of 9.25. The firm has a market cap of C$550.36 million, a PE ratio of -34.00, a P/E/G ratio of -1,013.50 and a beta of 0.49. Knight Therapeutics Inc. has a 12 month low of C$4.28 and a 12 month high of C$5.75.
Analyst Ratings Changes
Read Our Latest Stock Report on GUD
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Pros And Cons Of Monthly Dividend Stocks
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Election Stocks: How Elections Affect the Stock Market
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.